For lymphoid cancers, acute lymphoblastic leukemia, chronic lymphocytic leukemia and multiple myeloma, NR3C1 activation has been proven to be an effective treatment strategy. Here, NR3C1 is linked to B-cell chronic lymphocytic leukemia.